Home/Pipeline/Cannabics® MLN-33

Cannabics® MLN-33

Melanoma

PreclinicalActive

Key Facts

Indication

Melanoma

Phase

Preclinical

Status

Active

Company

CNBX Pharmaceuticals

About CNBX Pharmaceuticals

CNBX Pharmaceuticals is a clinical-stage biotech company developing a pipeline of cannabinoid-based drug candidates for cancer and neuropsychiatric disorders. Its core asset, RCC-33, is positioned as a first-in-class candidate for colorectal cancer, currently in late preclinical stages preparing for an IND. The company utilizes an in-house drug discovery platform centered on high-throughput screening of cannabinoid formulations against various cancer types. Leadership combines business acumen with scientific and clinical expertise, supported by a notable advisory board in oncology.

View full company profile

Therapeutic Areas

Oncology Neuropsychiatry Gastroenterology

Other Melanoma Drugs

Drug	Company	Phase	Status
ABD-3001	Advanced Biodesign	Phase 1	Active
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
AV-MEL-1	AIVITA Biomedical	Phase 1B	Active
Melanoma Immunotherapy	Vaccizone	Pre-clinical	Active
Undisclosed RNA Immunotherapy	Epitopea	Pre-clinical	Active
Melanoma Monitoring Solution	Oncobit	Commercial	Active
Undisclosed Enhanced Antibody Program	Score Pharma	Pre-clinical	Active
ASO for Melanoma	Carnation Therapeutics	Pre-clinical	Active
Personalized DNA Cancer Vaccine	Neomatrix	Pre-clinical	Active